Pharmaceuticals firm says third dose of its Covid vaccine increases antibodies against variant by 37-fold
The pharmaceuticals company Moderna has said a booster dose of its Covid vaccine appeared to protect against the fast-spreading Omicron variant in laboratory testing and that the current version will continue to be its “first line of defence against Omicron”.
The decision to focus on the current vaccine, mRNA-1273, was driven in part by how quickly the variant is spreading. The company plans to develop a vaccine specifically to protect against Omicron, which it hopes to advance into clinical trials early next year.
